Lv2
170 积分 2022-01-04 加入
Overcoming therapy resistance in EGFR-mutant lung cancer
5天前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
29天前
已完结
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer
1个月前
已完结
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
2个月前
已完结
Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations
2个月前
已完结
Intragenic ERBB2 kinase mutations in tumours
6个月前
已完结
Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine
6个月前
已完结
Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations
6个月前
已完结
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial
6个月前
已完结
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
6个月前
已完结
皖公网安备34019202002308
